193 related articles for article (PubMed ID: 37450376)
1. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Ayuk F; Gagelmann N; von Tresckow B; Wulf G; Rejeski K; Stelljes M; Penack O; Baldus CD; Kröger N; Bethge W; Dreger P
Blood Adv; 2023 Sep; 7(18):5316-5319. PubMed ID: 37450376
[No Abstract] [Full Text] [Related]
2. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
[No Abstract] [Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Alcantara M; Houillier C; Blonski M; Rubio MT; Willems L; Rascalou AW; Le Garff-Tavernier M; Maloum K; Bravetti C; Souchet L; Roos-Weil D; Morel V; Uzunov M; Metz C; Dhib-Charfi M; Nguyen S; Shor N; Psimaras D; Weiss N; Jacque N; Solorzano S; Gauthier N; Le Cann M; Norol F; Soussain C; Choquet S
Blood; 2022 Feb; 139(5):792-796. PubMed ID: 34871363
[No Abstract] [Full Text] [Related]
5. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
Dreger P; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner E; Wulf G; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Schroers R; Wolff D; Thomas S; Kröger N; Bethge WA; ;
Bone Marrow Transplant; 2023 Feb; 58(2):229-232. PubMed ID: 36418916
[No Abstract] [Full Text] [Related]
7. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
Thanarajasingam G; Maurer MJ; Farooq U; Johnston PB; Thompson CA; Bennani NN; Ansell SM; Porrata LF; Macon WR; Syrbu SI; Cerhan JR; Habermann TM; Link BK; Witzig TE; Nowakowski GS
Br J Haematol; 2018 Oct; 183(1):149-152. PubMed ID: 28961306
[No Abstract] [Full Text] [Related]
8. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
10. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
11. Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment.
Gokozan HN; Ouseph MM; Carniello JVS; Besien KV; Patel SS
Cytopathology; 2022 Nov; 33(6):757-759. PubMed ID: 35713946
[TBL] [Abstract][Full Text] [Related]
12. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
13. Central Nervous System Lymphoma.
Chukwueke UN; Nayak L
Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
[TBL] [Abstract][Full Text] [Related]
14. [Central nervous system involvement in diffuse large B-cell lymphoma: prevention and treatment].
Zhou D; Zhang W
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):284-5. PubMed ID: 24759011
[No Abstract] [Full Text] [Related]
15. Safety of CAR T-cell therapy in kidney transplant recipients.
Mamlouk O; Nair R; Iyer SP; Edwards A; Neelapu SS; Steiner RE; Adkins SA; Hawkins M; Saini N; Devashish K; Strati P; Mandayam S; Ahmed S
Blood; 2021 May; 137(18):2558-2562. PubMed ID: 33512386
[No Abstract] [Full Text] [Related]
16. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
18. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.
Fox CP; Phillips EH; Smith J; Linton K; Gallop-Evans E; Hemmaway C; Auer DP; Fuller C; Davies AJ; McKay P; Cwynarski K;
Br J Haematol; 2019 Feb; 184(3):348-363. PubMed ID: 30467845
[No Abstract] [Full Text] [Related]
20. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
